Literature DB >> 12642005

Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma.

Richard F. Little1, Wyndham H. Wilson.   

Abstract

AIDS-related non-Hodgkin's lymphoma (ARL) is an opportunistic malignancy that foreshortens life more than any other commonly occurring HIV-associated cancer. Treatment strategies include low-dose chemotherapy, chemotherapy given with antiretroviral therapy, and infusional chemotherapy regimens. Rituximab, an anti-CD20 monoclonal antibody, has been found to be useful in non-HIV-associated lymphomas and is of interest in ARL as well. Since the advent of highly active antiretroviral therapy, the ARL incidence and survival has changed. This paper reviews the epidemiologic, biologic, and clinical features of ARL with the aim of presenting a cohesive overview of these elements.

Entities:  

Year:  2003        PMID： 12642005     DOI： 10.1007/s11908-003-0055-1

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.663


  74 in total

1.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

Authors:  R D Gascoyne; S A Adomat; S Krajewski; M Krajewska; D E Horsman; A W Tolcher; S E O'Reilly; P Hoskins; A J Coldman; J C Reed; J M Connors
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

2.  Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas.

Authors:  A Carbone; A Gloghini; L M Larocca; D Capello; F Pierconti; V Canzonieri; U Tirelli; R Dalla-Favera; G Gaidano
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

3.  Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

Authors:  L D Kaplan; D J Straus; M A Testa; J Von Roenn; B J Dezube; T P Cooley; B Herndier; D W Northfelt; J Huang; A Tulpule; A M Levine
Journal:  N Engl J Med       Date:  1997-06-05       Impact factor: 91.245

4.  Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis.

Authors:  O W Kamel; M van de Rijn; L M Weiss; G J Del Zoppo; P K Hench; B A Robbins; P G Montgomery; R A Warnke; R F Dorfman
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

5.  Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial.

Authors:  T P Miller; T M Grogan; S Dahlberg; C M Spier; R M Braziel; P M Banks; K Foucar; C R Kjeldsberg; N Levy; B N Nathwani
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

6.  Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen.

Authors:  J A Sparano; P H Wiernik; M Strack; A Leaf; N H Becker; C Sarta; D Carney; R Elkind; M Shah; E S Valentine
Journal:  Leuk Lymphoma       Date:  1994-07

7.  Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.

Authors:  W H Wilson; J Teruya-Feldstein; T Fest; C Harris; S M Steinberg; E S Jaffe; M Raffeld
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

8.  Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients.

Authors:  M Spina; E Vaccher; S Juzbasic; I Milan; G Nasti; R Talamini; M Fasan; A Antinori; E Nigra; U Tirelli
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

9.  Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival.

Authors:  A M Levine; J Sullivan-Halley; M C Pike; M U Rarick; C Loureiro; M Bernstein-Singer; E Willson; R Brynes; J Parker; S Rasheed
Journal:  Cancer       Date:  1991-12-01       Impact factor: 6.860

Review 10.  Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity.

Authors:  G Gaidano; C Pastore; C Lanza; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673
View more
  1 in total

Review 1.  How I treat HIV-associated lymphoma.

Authors:  Kieron Dunleavy; Wyndham H Wilson
Journal:  Blood       Date:  2012-02-15       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.